Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Acute Toxicity: oral

Currently viewing:

Administrative data

Endpoint:
acute toxicity: oral
Type of information:
read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
key study
Justification for type of information:
Please refer to chapter 13 for the read-across justification.
Cross-referenceopen allclose all
Reason / purpose for cross-reference:
read-across source
Reference
Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
weight of evidence
Study period:
12 Sept. 1973 to 03 Sept. 1974
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
study well documented, meets generally accepted scientific principles, acceptable for assessment
Principles of method if other than guideline:
According to BASF-internal standard: 5 Sprague-Dawley rats (per sex and per dose) were exposed to the test substance via oral gavage at a dose of 5000 mg/kg bw. After an observation period of 7 days animals were necropsied and examined for clinical signs.
GLP compliance:
no
Test type:
standard acute method
Limit test:
yes
Specific details on test material used for the study:
Name of the test substance used in the study report: Neozapongelb R (TDA) Chromium-1.2-complex

performed under old CAS 73297-13-9
new CAS 85029-58-9, same structure
Species:
rat
Strain:
Sprague-Dawley
Sex:
male/female
Details on test animals or test system and environmental conditions:
Mean body weight: males 176 g; females 166 g
Route of administration:
oral: gavage
Vehicle:
CMC (carboxymethyl cellulose)
Details on oral exposure:
Aqueous test substance preparation with CMC
Form of administration: suspension
Test concentration used: 16% (w/v)
Due to technical reasons, a higher test substance concentration (more than 16%) could not be administered.
Doses:
5000 mg/kg
No. of animals per sex per dose:
5
Control animals:
no
Details on study design:
- Duration of observation period following administration: 7 days
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs
Key result
Sex:
male/female
Dose descriptor:
LD50
Effect level:
> 5 000 mg/kg bw
Based on:
test mat.
Mortality:
None
Clinical signs:
other: Feces brown coloured.
Gross pathology:
Nothing abnormal detected.
Interpretation of results:
GHS criteria not met
Reason / purpose for cross-reference:
read-across source
Reference
Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
weight of evidence
Study period:
27 Feb. 1980
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
comparable to guideline study with acceptable restrictions
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 401 (Acute Oral Toxicity)
GLP compliance:
no
Test type:
standard acute method
Limit test:
no
Specific details on test material used for the study:
SOURCE OF TEST MATERIAL
- Name of test substance as cited in report: Neozapon-orange Vers. 1187 (pulvrig)
- Substance number as cited in report: 79-594

FORM AS APPLIED IN THE TEST
Suspension
Species:
rat
Strain:
Sprague-Dawley
Remarks:
Wiga
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Weight at study initiation: males, 170-190 g; females: 160-170 g
- Fasting period before study: 15 to 20 hours
- Diet: Herilan MRH-Haltung; H Eggersmann KG
Route of administration:
oral: gavage
Vehicle:
olive oil
Details on oral exposure:
VEHICLE
- Concentration in vehicle (%, g/v): from low to high dose: 16.5; 24.2; 35.6; 35.6; 35.6
- Amount of vehicle (mL/kg): from low to high dose: 5.0; 5.0; 5.0; 7.3; 10.8

MAXIMUM DOSE VOLUME APPLIED:
10.8 mL/kg
Doses:
825; 1210; 1780; 2610; 3830 mg/kg
No. of animals per sex per dose:
5, except for the 2610 mg/kg dose in males which was tested in 4 animals
Control animals:
no
Details on study design:
- Duration of observation period following administration: 14 days
- Frequency of observations: < 15min, 15 min, 30 min, 1 hour, 4 hours, 1 day, 2 days, 5 days, 6 days, 7 days, 8 days, 9 days, 12 days, 13 days, 14 days
- Frequency of weighing: 2-4, 7 and 13 days
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight, histopathology
Sex:
male/female
Dose descriptor:
LD50
Effect level:
1 400 mg/kg bw
Based on:
test mat.
Sex:
female
Dose descriptor:
LD50
Effect level:
1 200 mg/kg bw
Based on:
test mat.
Sex:
male
Dose descriptor:
LD50
Effect level:
1 600 mg/kg bw
Based on:
test mat.
Mortality:
- 825 mg/kg: no mortality was observed
- 1210 mg/kg: males, 3 animals died after 7 days; females, 3 animals died after 7 days
- 1780 mg/kg: males, 1 animal died after 7 days; females, 4 animals died after 7 days
- 2610 mg/kg: males, 4 (all) animals died after 7 days; females, 5 (all) animals died after 7 days
- 3830 mg/kg: males, 5 (all) animals died after 7 days; females, 5 (all) animals died after 7 days
Clinical signs:
other: - 825 mg/kg: Observed symptoms included orange faeces, orange urine, diarrhoea - 1210 mg/kg: Observed symptoms included orange faeces, orange urine, diarrhoea - 1780 mg/kg: Observed symptoms included orange faeces, orange urine, diarrhoea - 2610 mg/kg:
Gross pathology:
- Animals that died during the study: heart, acute dilation of the atria; acute hyperaemia; organs/adipose tissue/musculature: substance stained.
- Sacrificed animals: no effects observed
Interpretation of results:
Category 4 based on GHS criteria
Reason / purpose for cross-reference:
read-across source
Reference
Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
weight of evidence
Study period:
5 May 1972 to 12 May 1972
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
test procedure in accordance with national standard methods with acceptable restrictions
Principles of method if other than guideline:
Gassner rats were exposed to the test substance (5 animals/sex/dose) at dosages of 200, 2500, 3200, 4000, 5000, 6400, 8000 and 10000 mg/kg. After an observation period of 7 days surviving animals were sacrificed and pathological examination.
GLP compliance:
no
Test type:
standard acute method
Limit test:
no
Specific details on test material used for the study:
SOURCE OF TEST MATERIAL
- Name of test substance as cited in report: Neozaponorange RE (60-2819)
Species:
rat
Strain:
other: Gassner
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Weight at study initiation: Males, on average 244 g; females, on average 175 g
Route of administration:
oral: gavage
Vehicle:
CMC (carboxymethyl cellulose)
Details on oral exposure:
VEHICLE
- Application form: 30% aqueous suspension with carboxymethyl cellulose
Doses:
PRETEST
3200 and 6400 mg/kg

MAIN TEST
2000, 2500, 3200, 4000, 5000, 6400, 8000 and 10000 mg/kg
No. of animals per sex per dose:
5
Control animals:
no
Details on study design:
PRETESTS
- Duration of observation period following administration: 14 days

MAINTEST
- Duration of observation period following administration: 7 days
- Frequency of observations: 1 hour, 1 day, 2 days, 7 days
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, (histo)pathology
Preliminary study:
MORTALITY
- 3200 mg/kg: 0/5 males and 2/5 females died
- 6400 mg/kg: 3/5 males and 5/5 females died
Sex:
male/female
Dose descriptor:
LD50
Effect level:
5 500 mg/kg bw
Based on:
test mat.
Mortality:
- 2000 mg/kg: no mortality observed
- 2500 mg/kg: no mortality observed
- 3200 mg/kg: no mortality observed
- 4000 mg/kg: male: 1/5 at 7 days; no mortality among females
- 5000 mg/kg: no mortality among males; female: 3/5 at 7 days
- 6400 mg/kg: male: 1/5 at 2 days, 4/5 at 7 days; female, 1/5 at 2 days, 5/5 at 7 days
- 8000 mg/kg: male: 1/5 at 2 days, 5/5 at 7 days; female, 1/5 at 2 days, 5/5 at 7 days
- 10000 mg/kg: male: 1/5 at 2 days, 5/5 at 7 days; female, 1/5 at 2 days, 5/5 at 7 days
Clinical signs:
other: All treated animals showed immediately after application chewing movements and crouched after approximately 4 hours. From 4 days irregular breathing, orange colouring of the fur, eyes, ears, arms, legs, faeces and urine were observed. The animals from the
Gross pathology:
- Animals that died during the study: Finding included acute dilution of both heart chambers; general congestion hyperaemia; thin, pulpy and red-brown/orange stained stomach contents; diarrheal reddish contents in the intestines (containing blood in one case); red/orange coloured musculature and adipose tissue, very thin appearance and bloody erosions in the glandular stomach area.
- Animals that were sacrificed at the end of the study: Organs were slightly reddish coloured.
Interpretation of results:
GHS criteria not met

Data source

Materials and methods

Test material

Constituent 1
Chemical structure
Reference substance name:
Reaction mass of Amines, C10-14-branched and linear alkyl, bis[2,4-dihydro-4-[(2-hydroxy-5-nitrophenyl)azo]-5-methyl-2-phenyl-3H-pyrazol-3-onato(2-)]chromate(1-) (1:1) and Amines, C10-14-branched and linear alkyl, bis[2-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo]benzoato(2-)]chromate(1-) and Amines, C10-14-branched and linear alkyl, [2,4-dihydro-4-[(2-hydroxy-5-nitrophenyl)azo]-5-methyl-2-phenyl-3H-pyrazol-3-onato(2-)][2-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo]benzoato(2-)]chromate(1-)
EC Number:
943-133-8
Molecular formula:
C32H22CrN10O8.C10-14H21-29NH2 / C34H24CrN8O6.C10-14H21-29NH2 / C33H23CrN9O7.C10-14H21-29NH2
IUPAC Name:
Reaction mass of Amines, C10-14-branched and linear alkyl, bis[2,4-dihydro-4-[(2-hydroxy-5-nitrophenyl)azo]-5-methyl-2-phenyl-3H-pyrazol-3-onato(2-)]chromate(1-) (1:1) and Amines, C10-14-branched and linear alkyl, bis[2-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo]benzoato(2-)]chromate(1-) and Amines, C10-14-branched and linear alkyl, [2,4-dihydro-4-[(2-hydroxy-5-nitrophenyl)azo]-5-methyl-2-phenyl-3H-pyrazol-3-onato(2-)][2-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo]benzoato(2-)]chromate(1-)
Test material form:
solid

Results and discussion

Effect levelsopen allclose all
Key result
Sex:
female
Dose descriptor:
LD50
Effect level:
1 200 mg/kg bw
Based on:
test mat.
Remarks on result:
other: Result read-across source CAS No. 84961-40-0
Remarks:
Correction for molecular weight not necessary.
Sex:
male/female
Dose descriptor:
LD50
Effect level:
1 400 mg/kg bw
Based on:
test mat.
Remarks on result:
other: Result read-across source CAS No. 84961-40-0
Remarks:
Correction for molecular weight not necessary.
Sex:
male
Dose descriptor:
LD50
Effect level:
1 600 mg/kg bw
Based on:
test mat.
Remarks on result:
other: Result read-across source CAS No. 84961-40-0
Remarks:
Correction for molecular weight not necessary.
Sex:
male/female
Dose descriptor:
LD50
Effect level:
> 5 000 mg/kg bw
Based on:
test mat.
Remarks on result:
other: Result read-across source CAS No. 85029-58-9
Remarks:
Correction for molecular weight not necessary.
Sex:
male/female
Dose descriptor:
LD50
Effect level:
5 500 mg/kg bw
Based on:
test mat.
Remarks on result:
other: Result read-across source CAS No. 84961-59-0
Remarks:
Correction for molecular weight not necessary.

Applicant's summary and conclusion